Investors Face November Deadline in Ardelyx Securities Litigation

The lawsuit alleges that Ardelyx provided misleading information regarding the commercial performance of its products, XPHOZAH and IBSRELA. According to the complaint, the company allegedly concealed growing obstacles to patient access, including stringent prior authorization and step edit requirements that hampered prescription fulfillment and new-patient growth. Investors contend these omissions caused financial damage when the true nature of the company’s commercial standing reached the market.

Those who purchased shares during the specified class period may be eligible for compensation through a contingency fee arrangement. While a lawsuit has been filed, no class has been certified yet. Investors retain the right to select their own counsel, remain an absent class member, or move the court to serve as a lead plaintiff by the November cutoff. Parties interested in participating can contact Phillip Kim at the Rosen Law Firm for further legal guidance.